BR112012018703A2 - compostos e seus efeitos sobre o comportamento alimentar - Google Patents

compostos e seus efeitos sobre o comportamento alimentar

Info

Publication number
BR112012018703A2
BR112012018703A2 BR112012018703A BR112012018703A BR112012018703A2 BR 112012018703 A2 BR112012018703 A2 BR 112012018703A2 BR 112012018703 A BR112012018703 A BR 112012018703A BR 112012018703 A BR112012018703 A BR 112012018703A BR 112012018703 A2 BR112012018703 A2 BR 112012018703A2
Authority
BR
Brazil
Prior art keywords
compounds
effects
reduction
eating behavior
analogs
Prior art date
Application number
BR112012018703A
Other languages
English (en)
Inventor
Stephen Robert Bloom
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of BR112012018703A2 publication Critical patent/BR112012018703A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G23/00—Driving gear for endless conveyors; Belt- or chain-tensioning arrangements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G2812/00—Indexing codes relating to the kind or type of conveyors
    • B65G2812/02—Belt or chain conveyors
    • B65G2812/02267—Conveyors having endless traction elements
    • B65G2812/02277—Common features for chain conveyors
    • B65G2812/02287—Driving means
    • B65G2812/02306—Driving drums
    • B65G2812/02316—Driving drums with means for assuring constant linear speed of chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mechanical Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

compostos e seus efeitos sobre o comportamento alimentar. a presente invenção refere-se a análagos de peptídeo de pyy, composições compreendendo os referidos análagos e métodos de uso dos referidos análagos para o tratamento e prevenção de distúrbios metabólicos, por exemplo, distúrbios de metabolismo de energia, tal como diabetes e obesiddae, e para uma redução no apetite, redução na ingestão de alimento oudredação de ingestão de caloria em um indivíduo.
BR112012018703A 2010-01-27 2011-01-27 compostos e seus efeitos sobre o comportamento alimentar BR112012018703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1001333.2A GB201001333D0 (en) 2010-01-27 2010-01-27 Novel compounds and their effects on feeding behaviour
PCT/GB2011/000110 WO2011092473A1 (en) 2010-01-27 2011-01-27 Novel compounds and their effects on feeding behaviour

Publications (1)

Publication Number Publication Date
BR112012018703A2 true BR112012018703A2 (pt) 2017-01-10

Family

ID=42084054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018703A BR112012018703A2 (pt) 2010-01-27 2011-01-27 compostos e seus efeitos sobre o comportamento alimentar

Country Status (13)

Country Link
US (1) US9018160B2 (pt)
EP (1) EP2528942B1 (pt)
JP (1) JP2013518090A (pt)
KR (1) KR20120127610A (pt)
CN (1) CN102741278A (pt)
AU (1) AU2011210165B2 (pt)
BR (1) BR112012018703A2 (pt)
CA (1) CA2788013A1 (pt)
GB (1) GB201001333D0 (pt)
MX (1) MX2012008792A (pt)
RU (1) RU2012136530A (pt)
SG (1) SG182578A1 (pt)
WO (1) WO2011092473A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
CA2909045C (en) * 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
WO2015177573A1 (en) * 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
US20170137486A1 (en) 2014-05-23 2017-05-18 Imperial Innovations Limited Peptide yy (pyy) analogues
WO2017021890A1 (en) * 2015-08-04 2017-02-09 Goal Zero Llc Portable solar panel system control
US11259554B2 (en) 2015-12-16 2022-03-01 Diet4Life Aps Dietary peptides
GB201720188D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
CA3087733A1 (en) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
GB201908426D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
MX2022013024A (es) 2020-04-17 2023-03-15 I2O Therapeutics Inc Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP3419454B2 (ja) 1991-11-06 2003-06-23 ガーヴァン インスティチュート オブ メディカル リサーチ ヒト神経ペプチドｙ−ｙ１レセプター
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
AU2005211755B2 (en) 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005211776B2 (en) 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
BRPI0507585A (pt) * 2004-03-17 2007-07-03 7Tm Pharmas As agonistas seletivos do receptor y2 para intervenções terapêuticas
CN1953763A (zh) 2004-03-17 2007-04-25 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
EP2060266B1 (en) 2004-03-17 2011-08-10 7TM Pharma A/S Y4 selective receptor agonist PP2-36 for therapeutic interventions
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
JP2008515443A (ja) 2004-10-08 2008-05-15 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規のアミリンファミリーポリペプチド−６（ａｆｐ−６）アナログならびにそれらの製法および使用方法
JP5743371B2 (ja) * 2004-12-13 2015-07-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP4629488B2 (ja) 2005-04-28 2011-02-09 本田技研工業株式会社 プラントを制御する制御装置
EP1907008A2 (en) 2005-07-11 2008-04-09 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
KR101399178B1 (ko) * 2005-08-11 2014-06-18 아스트라제네카 파마수티컬스 엘피 선별가능한 특성을 갖는 하이브리드 폴리펩티드
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2010533157A (ja) 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド ヒト膵臓ポリペプチド（ｈｐｐ）類似体および摂食行動に対するそれらの影響
EP2195034A2 (en) * 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
EP2279204A1 (en) * 2008-05-16 2011-02-02 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists

Also Published As

Publication number Publication date
CN102741278A (zh) 2012-10-17
AU2011210165A1 (en) 2012-08-23
SG182578A1 (en) 2012-08-30
AU2011210165B2 (en) 2014-06-05
JP2013518090A (ja) 2013-05-20
CA2788013A1 (en) 2011-08-04
GB201001333D0 (en) 2010-03-17
EP2528942B1 (en) 2020-06-17
RU2012136530A (ru) 2014-03-10
EP2528942A1 (en) 2012-12-05
WO2011092473A1 (en) 2011-08-04
US20130023464A1 (en) 2013-01-24
KR20120127610A (ko) 2012-11-22
US9018160B2 (en) 2015-04-28
MX2012008792A (es) 2012-11-29
WO2011092473A8 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
BR112012018703A2 (pt) compostos e seus efeitos sobre o comportamento alimentar
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
ECSP088849A (es) Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BR112014004890A8 (pt) Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria
BR112013011249A2 (pt) inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112013000537A2 (pt) composição aquosa contendo bromexina
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2007000078A (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CR10402A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BRPI0822069B8 (pt) método para preparação de um extrato de fruta de cardo leiteiro
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112014003640A2 (pt) métodos para perda de peso e composições cetogênicas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]